Skip to main content

Table 3 Subgroup Analysis of TXA and placebo

From: The efficacy of tranexamic acid treatment with different time and doses for traumatic brain injury: a systematic review and meta-analysis

 

Mortality

Adverse Events

Neurosurgical Intervention

Rebleeding

Mean hemorrhage volume

 

RR,

95%

P-Value

RR,

95%

P-Value

RR,

95%

P-Value

RR,

95%

P-Value

RR,

95%

P-Value

Study design

 Multisite RCT

0.99

[0.79–1.24]

0.90

0.91

[0.73–1.13]

0.38

1.01

[0.61–1.55]

0.96

0.81

[0.59–1.10]

0.17

-0.08

[-0.32, 0.16]

0.52

 Single site RCT

1.03

[0.73–1.43]

0.88

1.07

[0.39–2.88]

0.90

1.15

[0.89–1.48]

0.29

1.65

[0.94–2.89]

0.88

-0.46

[-0.72, -0.20]

0.0005

Enrollment time after trauma

 < 3 h

0.94

[0.87–1.02]

0.15

0.91

[0.77–1.08]

0.28

1.18

[0.89–1.55]

0.24

0.91

[0.75–1.10]

0.34

-0.50

[-0.94, -0.05]

0.03

 > 3 h

0.76

[0.51–1.11]

0.15

2.45

[0.92–6.52]

0.07

1.00

[0.70–1.44]

0.99

1.14

[0.65–2.02]

0.64

-0.33

[-0.65, 0.00]

0.05

TXA dose

 2 g TXA bolus followed by a placebo infusion

0.80

[0.56–1.15]

0.22

1.22

[0.85–1.74]

0.28

N/A

N/A

1.24

[0.91–1.70]

0.17

N/A

N/A

 1 g TXA bolus followed by 1 g TXA maintenance

1.01

[0.82–1.24]

0.95

1.00

[0.92–1.08]

0.97

N/A

N/A

1.00

[0.71–1.41]

1

N/A

N/A

  1. N/A Not applicable